HCPLive Podcasts

HCPLive.com
  • 5.0 (4)
  • MEDICINE
  • UPDATED WEEKLY

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

  1. HCPLive 5 Stories in Under 5: Week of 02/15

    1H AGO

    HCPLive 5 Stories in Under 5: Week of 02/15

    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous NephropathyObinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial, supporting a potential new B-cell–targeted standard of care. Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or OverweightIn adults with moderate-to-severe plaque psoriasis and obesity or overweight, combination therapy with ixekizumab and tirzepatide achieved superior skin clearance and weight reduction at 36 weeks compared with ixekizumab alone. AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSVReal-world data from over 2.5 million patients showed GSK’s AREXVY vaccine was 75.6% effective against RSV-related hospitalization, with additional signals suggesting reduced in-hospital major adverse cardiovascular events in older adults. COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRDCOMP360 synthetic psilocybin met the primary endpoint in its second phase 3 trial in treatment-resistant depression, demonstrating significant symptom reduction at week 6 versus low-dose control and advancing toward potential regulatory submission. Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip PlatformPreclinical data using a human liver-on-a-chip model suggest Thykamine may exert dose-dependent antifibrotic and anti-inflammatory effects in MASH, supporting further translational development.

    6 min
  2. ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH

    5D AGO

    ICD-10 Adoption and the True Burden of Short Bowel Syndrome With Alan Buchman, MD, MSPH

    Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology.  In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications.  His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice. Key Interview Time Stamps0:00:00 What prompted this analysis of ICD code adoption in short bowel syndrome?0:01:17 Key findings 0:03:33 Understanding reasons for variability in code adoption0:04:36 The potential benefits of improved coding accuracy

    7 min
  3. When Platelet Increments Matter, With Ruchika Goel, MD

    FEB 13

    When Platelet Increments Matter, With Ruchika Goel, MD

    HCPLive Podcasts

    7 min
  4. HCPLive 5 Stories in Under 5: Week of 02/01

    FEB 9

    HCPLive 5 Stories in Under 5: Week of 02/01

    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for February 1-7, 2026:1. FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic ReactionsThe FDA issued a Complete Response Letter for sublingual dibutepinephrine after identifying human factors issues that could compromise safe use during anaphylaxis, underscoring the importance of reliable administration in emergency settings. 2. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic DermatitisPhase 2 data indicate roflumilast cream was well tolerated in infants with atopic dermatitis and showed early signs of clinical improvement, supporting potential expansion of topical PDE4 inhibition into this very young population. 3. FDA Accepts Resubmitted BLA for RelabotulinumtoxinA for Glabellar and Lateral Canthal LinesThe FDA accepted Galderma’s resubmitted BLA for relabotulinumtoxinA following manufacturing process updates, allowing regulatory review to resume for treatment of glabellar and lateral canthal lines. 4. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with VitiligoAbbVie submitted regulatory applications seeking to expand upadacitinib use to adults and adolescents with non-segmental vitiligo, positioning a systemic JAK inhibitor as a potential option for this underserved condition. 5. VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2DPositive phase 2b results suggest Pfizer’s long-acting GLP-1 receptor agonist may support sustained weight management with extended dosing intervals in patients without diabetes.

    5 min
  5. Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

    FEB 4

    Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

    In this episode of Liver Lineup: Updates and Unfiltered Insights, Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes. Key episode timestamps:0:00:00 – Intro + global MASLD burden and mortality; who progresses to severe liver disease.0:03:00 – Very low disease awareness; advanced MASLD often missed.0:06:32 – Weak FIB‑4–based referral patterns; need automated pathways.0:10:54 – Alcohol underreporting; role of PEth in honest discussions.0:15:18 – “Modest” alcohol still harmful in MASLD; no truly safe level.0:19:40 – Semaglutide/GLP‑1 benefits on liver outcomes beyond weight loss.0:23:22 – FGF‑21 agents improving portal hypertension in advanced disease.0:24:03 – Carvedilol less effective for variceal bleed prevention in MASLD.0:28:45 – Closing remarks; call for better disease control and systems of care.

    29 min
  6. Liver Lineup: Advances, Gaps, and What’s Next in Viral Hepatitis

    FEB 4

    Liver Lineup: Advances, Gaps, and What’s Next in Viral Hepatitis

    In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions. Key episode timestamps:0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers.0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease.0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed.0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group.0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues.0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early HCC.

    29 min
  7. Liver Lineup: Bridging Innovation and Practice in Liver Transplant and HCC Care

    FEB 4

    Liver Lineup: Bridging Innovation and Practice in Liver Transplant and HCC Care

    In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down new research on liver transplantation, hepatocellular carcinoma (HCC), and the ongoing evolution of surveillance strategies in chronic liver disease. Drawing on their extensive experience as transplant hepatologists, Brown and Reau place new data into practical context, highlighting where evidence may meaningfully inform practice and where unanswered questions remain. Key episode timestamps:0:00:00 – Introduction0:00:19 – Frailty & Transplant Evaluation0:02:54 – How Centers Use Frailty Measures0:04:37 – Practicalities of the Six‑Minute Walk0:06:10 – MELD 3.0 and Sex/Size Disparities0:08:42 – Exception Points & Size Constraints0:10:05 – Need for a Dynamic MELD System0:10:19 – Immunotherapy as Bridge/Downstaging for HCC0:13:34 – Real‑World Use of IO Around Transplant0:15:22 – Managing Rejection Risk0:19:03 – MASLD Population & Surveillance Gaps0:20:21 – Adherence to HCC Surveillance0:22:42 – Practical Barriers: AFP, Ultrasound, Radiology Reports0:24:02 – Shift Toward Blood-Based Surveillance0:26:01 – How AFP-L3 and DCP Are Used in Practice0:27:39 – Rising AFP, Imaging Strategy & Broader Trend to Blood Tests0:28:27 – Guidelines vs Real-World Practice0:29:37 – Closing Thoughts on Guidelines & Early Detection

    31 min
  8. Liver Lineup: Advances in Portal Hypertension and Cirrhosis Management

    FEB 4

    Liver Lineup: Advances in Portal Hypertension and Cirrhosis Management

    In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down several of the most consequential hepatology developments of 2025, focusing on practical advances in the management of patients with advanced liver disease. From renal protection in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis to long-debated questions around albumin dosing and emerging tools for monitoring hepatic encephalopathy at home, the discussion centers on how new data may begin to shift everyday clinical decision-making. Key episode timestamps:0:00:00 – Dapagliflozin in MASLD cirrhosis with ascites0:04:41 – Clinical perspective on dapagliflozin & management strategy0:06:37 – Albumin for hyponatremia in cirrhosis0:12:28 – How clinicians currently use albumin in practice0:18:43 – Low‑dose vs conventional‑dose albumin in high‑risk SBP 0:25:03 – Beacon device: at‑home critical flicker frequency for HE0:27:47 – Future of at‑home HE monitoring & closing remarks

    28 min
See All (231)

Ratings & Reviews

5
out of 5
4 Ratings

About

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

Information

  • Creator
    HCPLive.com
  • Years Active
    2019 - 2026
  • Episodes
    231
  • Rating
    Clean
  • Show Website
    HCPLive Podcasts